Unresectable Extrahepatic Bile Duct Cancer Completed Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0028791 (Unresectable Extrahepatic Bile Duct Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00356889Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary TumorsTreatment